Antimicrobial-sensing proteins in obesity and type 2 diabetes: The buffering efficiency hypothesis

Diabetes Care

Volumn 34, Issue SUPPL. 2, 2011, Pages

  Moreno Navarrete, José María ^a   Fernández Real, José Manuel ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA DEFENSIN; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BIOLOGICAL MARKER; BUFFER; INSULIN; INSULIN RECEPTOR; LACTOFERRIN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; LYMPHOCYTE ANTIGEN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; REACTIVE OXYGEN METABOLITE; SOLUBLE CD14 ANTIGEN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; CATIONIC ANTIMICROBIAL PROTEIN 57, HUMAN; PLASMA PROTEIN;

DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG POTENTIATION; GRANULOCYTE; HUMAN; IN VITRO STUDY; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEUKOCYTE; LIFESTYLE; METABOLIC DISORDER; NEUTROPHIL; NEUTROPHILIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITION; OBESITY; POLYMORPHONUCLEAR CELL; PROTEIN FUNCTION; REVIEW; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO; METABOLISM; PATHOLOGY;

ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD PROTEINS; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLIC DISEASES; NEUTROPHILS; OBESITY;

EID: 79959775413     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-s238     Document Type: Review

References (61)

1. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867 (Pubitemid 46024993)
2. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24:278-301 (Pubitemid 36724371)
3. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25:4-7 (Pubitemid 38032801)
4. Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 1997; 272:971-976 (Pubitemid 27034588)
5. Senn JJ, Klover PJ,Nowak IA,Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002;51: 3391-3399 (Pubitemid 35403441)
6. He J, Usui I, Ishizuka K, et al. Interleukin- 1alpha inhibits insulin signaling with phosphorylating insulin receptor substrate-1 on serine residues in 3T3-L1 adipocytes. Mol Endocrinol 2006;20:114-124 (Pubitemid 43011674)
7. Krogh-Madsen R, Plomgaard P, Møller K, Mittendorfer B, Pedersen BK. Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab 2006;291:E108-E114 (Pubitemid 44035315)
8. Lee JY, Hwang DH. The modulation of inflammatory gene expression by lipids: mediation through Toll-like receptors. Mol Cells 2006;21:174-185
9. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761-1772 (Pubitemid 47025442)
10. Tan KC, Chow WS, Tam S, Bucala R, Betteridge J. Association between acutephase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 2004;27:223-228 (Pubitemid 38196736)
11. Fernández-Real JM, López-Bermejo A, Vendrell J, Ferri MJ, Recasens M, Ricart W. Burden of infection and insulin resistance in healthy middle-aged men. Diabetes Care 2006;29:1058-1064 (Pubitemid 44115244)
12. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004;24: 816-823 (Pubitemid 38620857)
13. Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab 1992;18:187-201
14. Wang H,Meng QH, Gordon JR, Khandwala H, Wu L. Proinflammatory and proapoptotic effects of methylglyoxal on neutrophils from patients with type 2 diabetes mellitus. Clin Biochem 2007;40:1232-1239 (Pubitemid 47562425)
15. Hatanaka E, Monteagudo PT, Marrocos MS, Campa A. Neutrophils and monocytes as potentially important sources of proinflammatory cytokines in diabetes. Clin Exp Immunol 2006;146: 443-447 (Pubitemid 44722162)
16. Advani A, Marshall SM, Thomas TH. Impaired neutrophil actin assembly causes persistent CD11b expression and reduced primary granule exocytosis in type II diabetes. Diabetologia 2002;45:719-727 (Pubitemid 34810697)
17. Moreno-Navarrete JM, Ortega FJ, Bassols J, Ricart W, Fernández- Real JM. Decreased circulating lactoferrin in insulin resistance and altered glucose tolerance as a possible marker of neutrophil dysfunction in type 2 diabetes. J Clin EndocrinolMetab 2009;94: 4036-4044
18. Walrand S, Guillet C, Boirie Y, VassonMP. In vivo evidences that insulin regulates human polymorphonuclear neutrophil functions. J Leukoc Biol 2004;76:1104-1110 (Pubitemid 39602945)
19. Okouchi M,OkayamaN, Shimizu M,OmiH, Fukutomi T, Itoh M. High insulin exacerbates neutrophil-endothelial cell adhesion through endothelial surface expression of intercellular adhesionmolecule- 1 via activation of protein kinase C and mitogen-activated protein kinase. Diabetologia 2002;45:556-559 (Pubitemid 34533835)
20. Walrand S, Moreau K, Caldefie F, et al. Specific and nonspecific immune responses to fasting and refeeding differ in healthy young adult and elderly persons. Am J Clin Nutr 2001;74:670-678 (Pubitemid 33015154)
21. Walrand S, Guillet C, Boirie Y, VassonMP. Insulin differentially regulates monocyte and polymorphonuclear neutrophil functions in healthy young and elderly humans. J Clin Endocrinol Metab 2006;91:2738-2748 (Pubitemid 44024646)
22. Stegenga ME, van der Crabben SN, Blümer RM, et al. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood 2008;112:82-89
23. Elgazar-Carmon V, Rudich A, Hadad N, Levy R. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J Lipid Res 2008;49: 1894-1903
24. Fernández-Real JM, García-Fuentes E, Moreno-Navarrete JM, et al. Fat overload induces changes in circulating lactoferrin that are associated with postprandial lipemia and oxidative stress in severely obese subjects. Obesity (Silver Spring) 2010;18:482-488
25. Pilvi TK, Harala S, Korpela R, Mervaala EM. Effects of high-calcium diets with different whey proteins on weight loss and weight regain in high-fat-fed C57BL/6J mice. Br J Nutr 2009;102:337-341
26. Baker EN, Baker HM. Molecular structure, binding properties and dynamics of lactoferrin. CellMol Life Sci 2005;62:2531-2539 (Pubitemid 41721228)
27. Håversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA, Mattsby-Baltzer I. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NFkappa B. Cell Immunol 2002;220:83-95 (Pubitemid 36349060)
28. Moreno-Navarrete JM, Ortega FJ, Bassols J, Castro A, Ricart W, Fernández-Real JM. Association of circulating lactoferrin concentration and 2 nonsynonymous LTF gene polymorphisms with dyslipidemia in men depends on glucose-tolerance status. Clin Chem 2008;54:301-309 (Pubitemid 351302631)
29. Moreno-Navarrete JM, Ortega FJ, RicartW, Fernandez-Real JM. Lactoferrin increases (172Thr)AMPK phosphorylation and insulin-induced (p473Ser)AKT while impairing adipocyte differentiation. Int J Obes (Lond) 2009;33:991-1000
30. Gazzano-Santoro H, Parent JB, Conlon PJ, et al. Characterization of the structural elements in lipid A required for binding of a recombinant fragment of bactericidal/ permeability-increasing protein rBPI23. Infect Immun 1995;63:2201-2205
31. Horwitz AH, Leigh SD, Abrahamson S, et al. Expression and characterization of cysteinemodified variants of an amino-terminal fragment of bactericidal/permeabilityincreasing protein. Protein Expr Purif 1996; 8:28-40 (Pubitemid 26326211)
32. Gubern C, López-Bermejo A, Biarnés J, Vendrell J, Ricart W, Fernández-Real JM. Natural antibiotics and insulin sensitivity: the role of bactericidal/permeabilityincreasing protein. Diabetes 2006;55: 216-224 (Pubitemid 43343318)
33. Esteve E, Castro A,Moreno JM, Vendrell J, Ricart W, Fernández-Real JM. Circulating bactericidal/permeability-increasing protein (BPI) is associated with serum lipids and endothelial function.ThrombHaemost 2010;103:780-787
34. Schneider JJ, Unholzer A, Schaller M, Schäfer-Korting M, Korting HC. Human defensins. J Mol Med 2005;83:587-595 (Pubitemid 41176067)
35. López-Bermejo A, Chico-Julià B, Castro A, et al. Alpha defensins 1, 2, and 3: potential roles in dyslipidemia and vascular dysfunction in humans. Arterioscler Thromb Vasc Biol 2007;27:1166-1171 (Pubitemid 46641973)
36. van Furth AM, Verhard-Seijmonsbergen EM, Langermans JA, van Dissel JT, van Furth R. Anti-CD14 monoclonal antibodies inhibit the production of tumor necrosis factor alpha and interleukin-10 by human monocytes stimulated with killed and live Haemophilus influenzae or Streptococcus pneumoniae organisms. Infect Immun 1999;67:3714-3718 (Pubitemid 29356982)
37. Lee JD, Kato K, Tobias PS, Kirkland TN, Ulevitch RJ. Transfection of CD14 into 70Z/3 cells dramatically enhances the sensitivity to complexes of lipopolysaccharide (LPS) and LPS binding protein. J Exp Med 1992;175:1697-1705
38. Bazil V, Strominger JL. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol 1991;147:1567-1574
39. Landmann R, Zimmerli W, Sansano S, et al. Increased circulating soluble CD14 is associated with high mortality in gramnegative septic shock. J Infect Dis 1995; 171:639-644
40. Haziot A, Rong GW, Bazil V, Silver J, Goyert SM. Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-alpha production by cells in whole blood. J Immunol 1994;152:5868-5876 (Pubitemid 24174167)
41. Haziot A, Rong GW, Lin XY, Silver J, Goyert SM. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995;154:6529-6532
42. Read MA, Cordle SR, Veach RA, Carlisle CD, Hawiger J. Cell-free pool of CD14 mediates activation of transcription factor NF-kappa B by lipopolysaccharide in human endothelial cells. Proc Natl Acad Sci U S A 1993;90:9887-9891 (Pubitemid 23328215)
43. Troelstra A, Giepmans BN, Van Kessel KP, Lichenstein HS, Verhoef J, Van Strijp JA. Dual effects of soluble CD14 on LPS priming of neutrophils. J Leukoc Biol 1997;61:173-178 (Pubitemid 27081379)
44. Wurfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J ExpMed 1995; 181:1743-1754
45. Fernández-Real JM, Broch M, Richart C, Vendrell J, López-Bermejo A, Ricart W. CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J Clin Endocrinol Metab 2003;88: 1780-1784 (Pubitemid 36623404)
46. Fernández-Real JM, López-Bermejo A, Broch M, Vendrell J, Richart C, Ricart W. Circulating soluble CD14 monocyte receptor is associated with increased alanine aminotransferase. Clin Chem 2004;50: 1456-1458 (Pubitemid 38970666)
47. Fernández-Real JM, López-Bermejo A, Castro A, et al. Opposite relationship between circulating soluble CD14 concentration and endothelial function in diabetic and nondiabetic subjects. Thromb Haemost 2005;94:615-619 (Pubitemid 41300860)
48. Tobias PS, Soldau K, Ulevitch RJ. Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem 1989;264: 10867-10871 (Pubitemid 19161662)
49. Hailman E, Lichenstein HS, Wurfel MM, et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 1994;179:269-277 (Pubitemid 24012992)
50. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180:1025-1035 (Pubitemid 24256615)
51. Lepper PM, Schumann C, Triantafilou K, et al. Association of lipopolysaccharidebinding protein and coronary artery disease in men. J Am Coll Cardiol 2007;50:25-31 (Pubitemid 46963530)
52. Sun L, Yu Z, Ye X, et al. A marker of endotoxemia is associated with obesity and related disorders in apparently healthy Chinese. Diabetes Care 2010;33:1925-1932
53. Wang Y, Lam KS, Kraegen EW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007;53:34-41 (Pubitemid 46047761)
54. Yan QW, Yang Q, Mody N, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007;56:2533-2540 (Pubitemid 47523260)
55. Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Increased adipose tissue expression of lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities in humans. J Mol Med 2009;87:803-813
56. Moreno-Navarrete JM, Manco M, Ibáñez J, et al. Metabolic endotoxemia and saturated fat contribute to circulating NGAL concentrations in subjects with insulin resistance. Int J Obes (Lond) 2010;34:240-249
57. Law IK, Xu A, Lam KS, et al. Lipocalin-2 deficiency attenuates insulin resistance associated with ageing and obesity. Diabetes 2010;12:872-882
58. Kishore U, Greenhough TJ, Waters P, et al. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol 2006;43:1293-1315 (Pubitemid 43356370)
59. Fernández-Real JM, Chico B, Shiratori M, Nara Y, Takahashi H, RicartW. Circulating surfactant protein A (SP-A), a marker of lung injury, is associated with insulin resistance. Diabetes Care 2008;31:958-963
60. Fernández-Real JM, Valdés S, Manco M, et al. Surfactant protein d, a marker of lung innate immunity, is positively associated with insulin sensitivity. Diabetes Care 2010;33:847-853
61. Kim JY, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007;117:2621-2637 (Pubitemid 47494363)